Professional
Added to YB: 2025-01-15
Pitch date: 2025-01-13
BIIB [bullish]
Biogen Inc.
+16.13%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Market Cap
$24.8B
Pitch Price
$149.92
Price Target
300.00 (+72%)
Dividend
N/A
EV/EBITDA
7.78
P/E
15.38
EV/Sales
2.72
Sector
Biotechnology
Category
value
Show full summary:
Patient Capital Management Portfolio Holding: Biogen Inc.
BIIB: Trading below value of current drugs. Market ignores Alzheimer's potential, pipeline, and CEO's deal-making history. Intrinsic value estimate >2x current stock price. Significant upside potential with multiple catalysts overlooked.
Read full article (1 min)